Phagenyx

Phagenyx®

Neuromodulation System

Retrain the brain.
Restore swallowing control.

Stroke recovery starts here.

Dysphagia is Common, Costly and Harmful

Dysphagia is a significant and costly barrier to stroke recovery and is linked to prolonged hospitalization, increased healthcare costs and aspiration-related complications.

10+	day longer hospital stay[1]
$28k	additional cost per patient[2]
8x	higher mortality at 3 months[3]

The root cause of dysphagia

The root cause of neurogenic dysphagia is disruption to the nerves or brain areas involved in processing sensory information, resulting in loss of swallowing coordination and control. Conventional treatments often focus on compensatory techniques rather than addressing this underlying neurological disruption, limiting the potential for true functional recovery.

A New Approach to Improving Swallow Safety and Efficiency

Pharyngeal electrical stimulation (PES) is a targeted therapy that delivers low-level electrical impulses to the swallowing nerves in the throat, helping re-establish communication with the brain and promote neuroplasticity to restore swallowing control.[4]

1 STIMULATION OF SENSORY NERVES

2 SIGNALS EXCITE MOTOR CORTEX

3 EXCITATION DRIVES NEUROPLASTICITY

4 SWALLOWING CONTROL IS RESTORED

The Phagenyx® System

Harnessing the power of PES to retrain the brain and restore swallowing control.

The Phagenyx® System is the first and only clinically validated neuromodulation system that improves swallowing safety and efficiency by restoring the brain's ability to initiate and coordinate safe swallowing, accelerating recovery from severe dysphagia following stroke.

Treatment Catheter
- Stimulation + feeding
- 11.5F outer, 8F inner diameter
- Adjustable to fit adult anatomy

Base Station
- Intuitive touchscreen interface
- Personalized stimulation levels
- Electrode contact monitoring

10-Minute Treatment
1x daily for 3-6 days

Built for real-world care and supported by 30+ publications, Phagenyx® is proven to significantly improve patient outcomes and reduce length of stay.

- ✔ **Faster return to oral nutrition[5]**
- ✔ **Reduced aspiration risk[6]**
- ✔ **Shorter length of hospital stay[7]**

> 2X Improved Swallowing Safety[6]



6-Days Faster Return to Oral Nutrition[5]

8 Fewer Hospital Days[7]



Promotes Neurologic Recovery

Phagenyx applies pharyngeal electrical stimulation (PES) to the sensory nerves and restores the brain's control of swallowing function.

Improves Swallowing Safety & Efficiency

Clinical studies show Phagenyx enables faster return to oral nutrition and reduces aspiration risk, supporting shorter hospital stays.

Designed for Real-World Care

Phagenyx enables early intervention without disrupting clinical workflow – even for critically ill patients.

INTENDED USE

United States: Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Europe/UK/Switzerland: The Phagenyx System (EPSB3 Base Station and PNX1000- catheter) is to be used for the treatment of neurogenic dysphagia in adult patients. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

CE 2797 UKCA 0086

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M6 15SE, UK

1. Centers for Medicare & Medicaid Services (CMS). *Medicare Provider Analysis and Review (MedPAR)* File. Fiscal Year 2023.
2. Vasan V, et al. *J Stroke Cerebrovasc Dis.* 2023;32(9):107295.
3. Arnold M, et al. *PLoS One.* 2016;11(2):e0148424.
4. Fraser C, et al. *Neuron.* 2002;34(5):831–840.
5. Suntrup-Krueger S, et al. *Crit Care.* 2023;27(1):383.
6. Youssef G, et al. *Al-Azhar Assiut Med J.* 2015;13(1):68–72.
7. Suntrup-Krueger S, et al. *Crit Care.* 2025;May 17:e00613.

PHAGENESIS

www.phagenesis.com

PBO2EN_Rev.1